Peptide-Based Urinary Monitoring of Fibrotic Nonalcoholic Steatohepatitis by Mass-Barcoded Activity-Based Sensors

To identify a protease signature of nonalcoholic steatohepatitis (NASH), transcriptomic analysis of 355 human liver biopsies identified a 13-protease panel that discriminated clinically relevant NASH ≥F2 fibrosis from F0-F1 with high classification accuracy across two independent patient datasets.